Ovid Therapeutics Inc. (OVID) income statement
OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.26+0.04 (+1.80%)
Close on Nov 18, 2026Market cap $441.37MP/E –Yield –
Ovid Therapeutics Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -3686.7%
- Net margin
- -2178.9%
- Return on equity, FY2025
- -17.5%
Financial strength
- Current ratio
- 12.39
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 113.5%
Valuation
- P/E ratio
- –
- Price to sales
- 278.82
- Price to book
- 2.10
- Dividend yield
- –
See a number that looks wrong?